SGLT2-Antagonisten – ein Medikament gegen Diabetes und Bluthochdruck?

CardioVasc - 2016
Alexander Reshetnik1, Christopher Gohlisch, Markus van der Giet2
1Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Nephrologie und Tranplantationsmedizin, Hypertoniezentrum, Berlin, Deutschland
2Klinik für Nephrologie und Tranplantationsmedizin, Hypertoniezentrum

Tóm tắt

Từ khóa


Tài liệu tham khảo

Sowers JR, Epstein M and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9

Rahmouni K, Correia ML, Haynes WG and Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9–14

Ehrenkranz JR, Lewis NG, Kahn CR and Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8

Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75.e9

Solini A. Extra-glycaemic properties of empagliflozin. Diabetes Metab Res Rev. 2015. doi: 10.1002/dmrr.2666

Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74

List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7

Kim GRM, Andersen KR, Zeller C et al. Effect of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes. Diabetologia 2014;75(Suppl. 1):330, 818.

Ferrannini G, Hach T, Crowe S et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38:1730–5

Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97

Fu YGM, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 2014;63(Suppl. 1):512–P

Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. American journal of physiology. Ren Physiol. 2015;308:F1343–57

Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC med. 2013;11:43

Davies MJ, Trujillo A, Vijapurkar U et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–9

Ferrannini E, Berk A, Hantel S et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–21

Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens. 2012;14:346–52

Soletsky B and Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148–56